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Purpose: To investigate the penetration enhancing effect of two polysorbates - polyoxyethylene 20 
(POE-20) and polyoxyethylene 80 (POE-80) - on the in vitro percutaneous absorption of ascorbic acid 
(AA). 
Methods: For the permeation experiments, Franz diffusion cell covered with aluminum foil providing an 
effective diffusion area of 1.76 cm
2
 and hairless rabbit skin were used. A range of concentrations (1 – 5 
%) of POE-20 and POE-80 was added to the ascorbic acid to determine their optimum enhancement 
concentration.  
Results: The cumulative amount of AA that diffused across the skin increased with increase in the 
concentration of the permeation enhancers. Without the enhancer, AA flux was 0.626 µg/cm
2
/h while 
mean permeability coefficient (Kp) was 2.09 × 10
-6 
cm/h. AA flux was 3.17 and 2.44 µg/cm
2
/h for POE-20 
and POE-80, respectively, while mean permeability coefficient was 10.6 × 10
-6
 and 8.14 × 10
-6
 Kp, cm/h. 
Maximum flux (3.16 µg/cm
2
/h) at POE-20 concentration of 5 % was obtained, with an enhancement ratio 
(ER) of 5.07 in relation to control (i.e., AA without enhancer). For POE-80 (5 %), maximum flux was 2.44 
µg/cm
2
/h  with an ER value of 3.89, compared to control. 
Conclusion: This study demonstrates that POE-20 and POE-80 exerted a penetration enhancing effect 
on the percutaneous absorption of L-ascorbic acid (AA). 
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INTRODUCTION 
 
When a drug system is applied topically, the 
drug diffuses passively out of its carrier or 
vehicle. The two principal absorption routes 
are transepidermal (diffusion directly across 
the stratum corneum) and transfollicular 
(diffusion through the follicular pore). The 
stratum corneum is a source of high 
diffusional resistance to most compounds 
and thus constitutes the skin’s foremost 
barrier layer [1]. 
 
Percutaneous penetration enhancement 
techniques fall primarily into two categories: 
physical and chemical. Physical penetration 
enhancement involves an externally applied 
force to augment the delivery of the target 
agent across the skin [2] while in chemical 
penetration enhancement, penetration 
enhancers, which are compounds that alter 
the barrier properties of the stratum corneum 
by reversibly affecting the lipid bilayers or the 
protein structures in corneocytes, are used. 
Penetration enhancing compounds can 
induce skin irritation and may significantly 
alter stratum corneum lipids, in some cases, 
irreversibly. Non-ionic surfactants have not 
been reported to cause skin irritation [3]. 
 
Ascorbic acid (AA) is a vitamin for humans 
and other primates, guinea pig, bats, 
passeriform birds, and most fishes and 
invertebrates. Other animals synthesize it as 
an intermediate in the uronic acid pathway of 
glucose metabolism [4]. It is a colourless and 
odourless crystalline substance, slightly sour 
in taste and optically active. It is soluble in 
water and alcohol but practically insoluble in 
chloroform, solvent ether and light petroleum. 
It is readily oxidized, particularly in the 
presence of copper and iron. AA is also 
rapidly destroyed by alkalis. It is a powerful 
reducing agent [5]. 
 
Topical ascorbic acid (AA) has been shown 
to reduce chronic ultraviolet radiation damage 
in murine skin and to increase the minimal 
erythema dose (MED) value in human skin, 
indicating its value in providing UV barrier. 
Topical application of a 5 % AA cream has 
been shown to improve the clinical 
appearance of photo-damage as well as lead 
to dermal production of collagen and elastin 
discernible at the ultra structural level [6]. 
There are now data confirming the benefits of 
topically applied AA and supporting its use as 
a cosmeceutical [5]. A significant increase in 
AA levels after topical application of different 
AA derivatives, including magnesium 
ascorbyl phosphate, ascorbyl-6-palmitate and 
dehydroascorbic acid, to porcine skin could 
not be shown [6]. 
 
Polysorbate 80 and polysorbate 20 
are nonionic surfactants used in the 
manufacture of a variety of pharmaceutical pr
oducts. They are known to enhance the 
permeability of phospholipid membranes, 
causing leakage of low molecular mass 
compounds. Interaction between bio-
membranes and polysorbate 80 and 
polysorbate 20 has been shown in a 2 to 4-
fold increase in the synthesis rates of 
phospholipids, indicating that the 
polysorbates cause some damage to 
epidermal membranes. Furthermore, 
polysorbate  20 and 80 also induce alteration 
in the physicochemical properties of bio-
membranes, specifically, increase in the 
permeability of sarcoplasmic reticulum [7]. 
 
The aim of the present study was to examine 
the permeation enhancing effect of two 
polysorbates on the in vitro percutaneous 






Ascorbic acid (Merck, Germany), Tween 
(polysorbate) 80 (Merck, Germany), Tween 
(polysorbate) 20 (Fisher Scientific, UK), 
glycerin (Sarfraz Pharma, Pakistan), and a 
depilatory cream (Anne French, Pakistan) 
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Solubility study 
 
To determine the solubility of AA in 50 % 
aqueous glycerin, a large amount of AA was 
added to 2 ml of 50 % aqueous glycerin in a 
5 ml vial capped with a rubber stopper. The 
mixture was then blended slowly using 
magnetic stirrer coated with teflon. The 
equilibrated mixture was centrifuged for 15 
min at 5,000 rpm to get rid of the undissolved 
AA. A sample withdrawn from close to the 
surface of the supernatant was passed 
through a 0.45 µm membrane filter with the 
aid of a Millipore syringe filter unit, diluted 
appropriately with 50 % aqueous-glycerin 
mixture and the concentration of AA 
determined by UV spectrophotometry 
(Shimadzu 1601, Japan) at 264 nm [8] after 
suitable dilution with 50 % aqueous glycerin. 
Blank was 50 % aqueous glycerin. This 
determination was carried out in triplicate. 
 
Preparation of calibration curve for 
ascorbic acid 
 
An accurately weighed amount (100 mg) of 
AA was dissolved in 50 % aqueous glycerin 
and the volume was made up to 10 ml in a 
volumetric flask. An aliquot (0.1 ml) of this 
solution was transferred to a 10 ml volumetric 
flask and made up with 50 % aqueous 
glycerin to obtain 100 µg/ml stock solution. 
Aliquots of 0.2, 0.4, 0.6, 0.8, 1.2, and 1.6 ml, 
respectively, of the stock solution were 
separately diluted to 10 ml with aqueous 
glycerin to produce 2, 4, 6, 8, 12 and 16 
µg/ml solutions of AA, respectively. The 
absorbance of these solutions was 
determined spectrophotometrically against 
blank (50 % aqueous glycerin) at 264 nm. 
This test was performed in triplicate.  
 
Preparation of rabbit skin  
 
Rabbit skin was used to evaluate the 
percutaneous delivery of AA [6]. Male white 
rabbits, weighing 1 - 1.25 kg, were acquired 
from the animal house of the Department of 
Pharmacy, the Islamia University of 
Bahawalpur. The animal study was approved 
by The Islamia University of Bahawalpur 
Ethical Committee for In vivo Studies (ref no. 
45-IUB/M.Phil.), and was conducted 
according to the international guidelines of 
Helsinki Declaration [9]. 
 
The hair on the dorsal area of the rabbit was 
carefully shaved off with an electric hair 
clipper, avoiding any damage to the skin. A 
depilatory (hair removing cream) was applied 
to the shaved area to completely remove any 
residual hair and then cleaned with a wet 
cotton cloth. This procedure was carried out a 
day prior to excising the skin in order to allow 
the skin to condition itself to the environment. 
Thus, the same circular area on the back of 
each rabbit, marking out the specific skin 
segment to be placed between the two half 
cells, was used [10].  
 
The rabbit was sacrificed by cervical 
dislocation and the hairless skin was excised 
from the animal with surgical scissors. Since 
the skin was not firmly attached to the 
viscera, it was easily lifted from the animal 
after the incision was made. The 
subcutaneous fat and other extraneous 
tissues were removed with a scalpel [11]. Full 
thickness skin sections were prepared, rinsed 
with distilled water, wrapped in aluminum foil 
and stored at -50 
o
C (ultra-low temperature 
freezer, Sanyo, Japan) until used [7]. 
 
Examination of skin barrier integrity  
 
Before the experiment, the barrier integrity of 
the skin was checked by physical methods,. 
First, the integrity of the skin was assessed 
qualitatively by visual inspection and then by 
a transepidermal water loss (TEWL) 
apparatus, Tewameter™ (Courage + 
Khazaka, Germany). TEWL values before 
skin removal and after storage were 
obtained. Normal TEWL value of rabbit skin 
is 4 – 5 g/m
2
/h and so only specimens with 
TEWL levels of < 15 g/m
2
/h were used for 
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Preparation of formulations 
 
Test formulations were prepared by 
dissolving 400 mg of the drug (AA) in 2 ml of 
50 % aqueous glycerin solution in a small vial 
with the aid of a small stirrer coated with 
teflon. This formulation was a saturated 
solution based on the outcome of the 
solubility test carried out as described above. 
The solvent/medium used, i.e., 50 % 
aqueous glycerin, was selected due to the 
stability of AA in it [13]. Varying 
concentrations of the penetration enhancers 
(POE-20 and POE-80) in the formulations, 
ranging from 1 - 5 %, were achieved by 
dissolving amounts of the enhancers ranging 
from 20 - 100 mg of the enhancer in the AA 
solution. All the test formulations were freshly 
prepared and used immediately in the 
permeation study. The water used for all the 
solutions was distilled, de-ionized and 
degassed. Control formulation was similarly 
prepared except that enhancer was not 
added. 
 
Permeation studies  
 
The donor chamber solution chosen was 50 
% glycerin. It has previously been 
demonstrated that glycerin, when used as a 
donor solution, does not alter skin penetration 
characteristics [12]. The skin was saturated 
with the receptor solution for 12 h at 4 °C 
prior to the permeation test to equilibrate it 
[5]. The apparatus used was vertical Franz 
diffusion cell (PermeGear, Bethlehem, USA) 
with an effective diffusional surface area of 
1.767 cm
2
. The volume of the receptor 
chamber was approximately 12 ml. The 
receptor medium was poured into the lower 
(reveptor) chamber to fill it and the skin was 
sandwiched between the lower (receptor) and 
upper (donor) compartments, with the 
superficial horny layer facing the upper 
chamber. Since AA is sensitive to light, the 
whole set-up was wrapped in aluminum foil to 
minimize photodegradation [13]. Stretching of 
the skin, as evidenced by distortion or 
expansion of the circular outline, was 
corrected for and the half cells were held tight 
together by a stainless steel holder. Immense 
care was taken to keep air from being 
trapped beneath the skin [14]. If air bubble 
was noticed, the Franz cell was tilted to 
remove the bubble from the assembly via the 
side arm of the sampling port. The receptor 
compartment solution, which was stirred at 
600 rpm throughout the duration of the test 
with a teflon-coated small magnetic stirrer, 
was maintained at 37.0 ± 0.2 °C with the aid 
of a water bath equipped with a peristaltic 
pump. The donor compartment contained 1.5 
ml of the test formulation (corresponding to 
infinite dose conditions) and was also 
occluded with aluminum foil [4].  
 
Samples (0.14 ml) were withdrawn from the 
receptor compartment using a syringe fitted 
with a long needle at regular intervals for up 
to 11 h, diluted with 50 % aqueous glycerin 
solution and assayed spectrophotometrically 
at 264 nm (after appropriate dilution) against 
a blank comprising the test formulation but 
without the drug [9]. On each sampling 
occasion, the same volume of fresh receptor 
medium at 37 
0
C as was removed was added 
to the receptor compartment to replenish the 
receptor medium [12]. The test was carried 
out in duplicate.  
 
Computation of permeation data 
 
As a result of the sampling of large volumes 
from the receptor medium (and 
replenishment with equal volumes of the 
fresh medium), the receptor medium was 
constantly being diluted. Consequently, the 
receptor compartment concentration of AA 
was corrected for sample removal and 
replenishment using Eq 1 [15]. 
 
C'n = Cn (Vt / Vt-Vs) (C'n-1 / Cn-1)……..  (1) 
 
where C'n = corrected drug concentration in 
the nth sample, Cn = measured drug 
concentration in the nth sample, C'n-1 = 
corrected drug concentration in the (n-1)
th
 
sample, Cn-1 = measured drug concentration 
in the (n-1)
th
 sample, Vt = total volume of 
receptor solution, Vs = volume of the sample, 
and C'1 = C1. 
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Permeation rate 
 
The corrected data were expressed as the 
cumulative drug permeation per unit of skin 
surface area using Eq 2. 
 
Qn = C'n/A ……………………………....  (2) 
 
where A = 1.767 cm
2 
 
Steady-state flux (Jss) 
 
The cumulative amount of drug per unit area 
(Qn, µg) in the receiver chamber was plotted 
as a function of time (t, h), and steady-state 
flux (Jss, µg/h/cm
2
) was calculated from the 
slope of the linear portion (5 - 10 h) of the 
curve [9]. 
 
Permeability coefficient (Kp) 
 
Apparent permeability coefficient (Kp, cm/h) 
was calculated according to Eq 3. 
 
Kp = Jss/Cd ……………………….…..  (3) 
 
where Cd = drug concentration in the donor 
compartment, i.e., 20.0 % w/v (20.0×10
4
 
µg/ml). It was assumed that under sink 
conditions, drug concentration in the receptor 
compartment was negligible compared to that 




Enhancement ratio (ER), which measures the 
penetration enhancing activity of the 
enhancers, was calculated as in Eq 4. 
 
ER = Kp1/Kp0  ………………………  (4) 
 
where Kp0 is the permeability coefficient of 
control (i.e., without enhancer) and Kp1 is the 
permeability coefficient in the presence of 
enhancer.  
 
Diffusion coefficient (D) 
 
Diffusion coefficient (D) was calculated using 
Eq 5 [13]. 
 
Kp =  D/A
2





D = Kp x A
2
  ……………………………  (6)
 
 
where D and Kp are as defined above and A
2 




Statistical analysis of the experimental data 
was carried out by one way analysis of 
variance (ANOVA) at a significance level of p 




Solubility of ascorbic acid (AA) 
 
The solubility of AA in 50 % glycerin aqueous 
solution was 1 g/100 ml. The coefficient of 
regression (R
2
) of the standard solubility 
curve was 0.9997 while the regression 
equation was y = 0.0563x + 0.0047. 
 
In vitro permeation of AA  
 
Tables 1 and 2 show the effect of the 
penetration enhancers, POE-80 and POE-20, 
respectively, on the amount of ascorbic acid 
(AA) permeated across rabbit skin. The 
results show that as the concentration of 
penetration enhancer increased, AA 
permeation also increased. 
 
Other permeation data 
 
The other AA permeation data derived from 
this study, namely, steady state flux (Jss), 
permeability coefficient, diffusion coefficient 
and enhancement ratio are given in Tables 3 
and 4. Without the enhancer, AA flux was 
0.626 µg/cm
2
/h while mean permeability 
coefficient (Kp) was 2.09 × 10
-6 
cm/h. AA flux 
(µg/cm
2
/h) was 3.17 and 2.44 for POE-20 
and POE-80, respectively. Mean permeability 





 for POE-20 and POE-80, 
respectively. Maximum flux (3.17 µg/cm
2
/h) at 
POE-20 concentration of 5 % was observed 
with an enhancement ratio (ER) of 5.07 in 
relation to control (i.e., AA without enhancer)  
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Table 1: In vitro permeation (Qn) of ascorbic acid (AA) across rabbit skin in the presence of penetration 




Control 1% 2% 3% 4% 5% 
Time 
(h) 
Ascorbic acid permeated (Qn, µg/cm²) 
0 0 0 0 0 0 0 
1 0.67±0.03 0.59±0.02 1.24±0.02 0.69±0.03 0.62±0.04 0.81±0.02 
2 1.09±0.04 0.89±0.05 1.57±0.07 1.21±0.05 0.76±0.03 0.75±0.02 
4 1.38±0.07 0.75±0.02 2.54±0.09 2.15±0.08 2.83±0.07 1.56±0.04 
6 2.57±0.08 1.51±0.05 5.78±0.09 4.66±019 5.76±0.25 7.29±0.68 
8 3.64±0.49 3.39±0.27 10.66±1.12 8.64±0.24 9.25±0.47 10.65±0.93 
10 5.29±0.68 6.40±0.57 13.49±1.53 13.00±0.57 14.65±0.78 16.00±1.18 
11 5.64±0.72 10.96±0.97 14.40±1.91 15.70±0.76 17.88±1.01 19.30±1.87 
 
Table 2: In vitro permeation (Qn) of ascorbic acid (AA) across rabbit skin in the presence of penetration 




Control 1% 2% 3% 4% 5% 
Time 
(h) 
Ascorbic acid permeated (Qn, µg/cm²) 
0 0 0 0 0 0 0 
1 0.67±0.03 0.68±0.06 0.88±0.04 1.11±0.45 1.41±0.23 1.39±0.58 
2 1.09±0.32 1.12±0.51 0.69±0.09 0.75±0.05 0.48±0.72 0.74±0.48 
4 1.38±0.53 1.59±0.53 1.01±0.8 1.53±0.34 4.21±0.80 4.61±0.85 
6 2.57±0.63 5.64±0.83 2.96±0.99 4.29±0.58 7.90±0.94 8.56±0.93 
8 3.64±0.73 8.93±0.89 6.59±1.19 8.61±0.87 13.74±1.29 13.36±1.34 
10 5.29±0.79 12.26±1.92 12.56±1.86 12.27±1.18 18.66±1.58 20.92±1.93 
11 5.64±0.91 13.76±1.47 14.79±1.93 18.23±2.17 25.98±2.87 27.56±2.18 
 
Table 3: Some permeation parameters for penetration of ascorbic acid (AA) across rabbit skin in the 



















Control (0) 0.63 2.09 0.65 _-_ 
1 1.35 4.50 1.41 2.15 
2 1.74 5.88 1.84 2.81 
3 1.95 6.50 2.03 3.11 
4 2.14 7.13 2.23 3.41 
5 2.44 8.14 2.54 3.89 
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Table 4: Some permeation parameters for penetration of ascorbic acid (AA) across rabbit skin in the 



















Control (0) 0.63 2.09 0.65 _-_ 
1  1.73 5.75 1.80 2.75 
2 2.05 6.82 2.13 3.26 
3 2.24 7.47 2.33 3.57 
4 2.95 9.83 3.07 4.70 
5 3.17 10.60 3.30 5.08 
 
while maximum flux (2.44 µg/cm
2
/h) at POE-
80 concentration of 5 % was observed with 
an ER value of 3.89. The values of diffusion 
coefficient (cm
2
/h) were 3.30 × 10
-5
 and 2.54 
× 10
-5
 for POE-20 and POE-80, respectively. 
 
The magnitude of the various permeation 
paraneters varied with the content of 
penetration enhancer, with the magnitude 





Percutaneous drug absorption is thought to 
occur via various skin auxilae including hair 
follicles, sweat ducts and sebaceous glands 
at an early stage as well as at a steady state. 
It is believed that nonionic surfactants, as 
penetration enhancers, seep into the 
intercellular lipid bilayers of skin thereby 
decreasing the crystallinity of these lipid 
bilayers and amplifying their permeability 
characteristics [16]. Another mechanism of 
action of non-ionic surfactants is that they 
cause the emulsification of the sebum and 
hence increase the thermodynamic activity of 
the drug [17].  
 
Nonionic surfactants are widely used in 
topical formulations. Among these surfactants 
are the polysorbates (Tweens), including the 
ones used in this study. It is evident from the 
permeability coefficient (Kp) data that the 
penetration enhancers used in this study, 
polysorbate 20 (POE-20) and 80 (POE-80), 
increased the permeation of ascorbic acid 
(AA) through hairless rabbit skin in vitro, and 
that the effect of the enhancers was 
concentration-dependent. It would seem that 
the enhancers increased AA permeation by 
decreasing skin resistance to the diffusion of 
the drug. The faster penetration of the drug 
through skin due to the presence of POE-20 
and POE-80 can be explained by following 
mechanisms. First, adsorption and fusion of 
drug molecules onto the surface of skin, 
resulting in the high thermodynamic activity 
gradient of drug at the interface, which is the 
driving force for drug permeation. Second, 
the influence of penetration enhancer 
decreases stratum corneum hindrancebarrier 
characteristics. Third, modification in the 
structure of stratum corneum may result in 
more loose intracellular lipid barrier in the 
stratum corneum and thus become more 
permeable to permeation enhancers [19,20].  
 
The enhancement effect of POE-20, a 
polysorbate containing C12 saturated 
hydrophobic group, can be attributed to an 
enhancement in thermodynamic activity due 
to micellar complexation. In contrast, POE-80 
effect may be due to change in the barrier 
properties of the skin and in the vehicle-
stratum corneum partition coefficient. 
Sarpotdar and Tatz [22] observed an 
enhancement in the transdermal flux of 
hydrocortisone in the presence of nonionic 
surfactants, including POE-20 and POE-80. In 
another work, POE-80 was reported to improve 
the skin permeation of hydrocortisone and 
lidocaine [23]. It has also been shown that 
POE-20 accelerated the percutaneous 
absorption of 5-flourouracil and captopril, and 
particularly increased the transdermal flux of 
captopril [19-23]. These findings are largely in 
agreement with the results obtained in the 
present work.  
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CONCLUSION 
 
This work further supports the earlier claims 
of polysorbate 20 and 80 as penetration 
enhancers for transdermal delivery of drugs. 
Furthermore, the higher the concentration of 
the penetration enhancer, the higher the 
permeability of ascorbic acid (AA). Increase 
in AA permeation was achieved with 
enhancer concentrations as low as 1 %. This 
is important because these surfactants, being 
non-ionic, are much less damaging to the 
skin than other classes of surfactants and 
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